Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Mar;16(3):336-338.
doi: 10.1016/j.cgh.2017.11.025. Epub 2017 Nov 16.

Advantages and Limitations of the Federal Adverse Events Reporting System in Assessing Adverse Event Reporting for Eluxadoline

Victor Chedid  1 , Priya Vijayvargiya  1 , Michael Camilleri  1
Affiliations
Editorial

Advantages and Limitations of the Federal Adverse Events Reporting System in Assessing Adverse Event Reporting for Eluxadoline

Victor Chedid et al. Clin Gastroenterol Hepatol. 2018 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures: The authors have no conflicts of interest.

Comment on

References

    1. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med. 2012;367(17):1626–35. - PubMed
    1. Ford AC, Lacy BE, Talley NJ. Irritable Bowel Syndrome. N Engl J Med. 2017;376(26):2566–78. - PubMed
    1. Simren M, Palsson OS, Whitehead WE. Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. Current Gastroenterology Reports. 2017;19(4):15. - PMC - PubMed
    1. Cash BD, Lacy BE, Schoenfeld PS, Dove LS, Covington PS. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea. Am J Gastroenterol. 2017;112(2):365–74. - PMC - PubMed
    1. Camilleri M, Ford AC. Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches. In: Greenwood-Van Meerveld B, editor. Gastrointestinal Pharmacology. Cham: Springer International Publishing; 2017. pp. 75–113. - PubMed